Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

neuroendocrine carcinoma News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

Recent multi-omics profiling identifies homologous recombination repair hyperactivation as a therapeutic vulnerability in neuroendocrine cervical carcinoma. This discovery could inform future treatment strategies for this rare cancer type.

A case study published in PubMed details a patient with mixed neuroendocrine carcinoma and adenocarcinoma following ileal pouch-anal anastomosis. This research contributes to the understanding of rare cancer presentations in patients with surgical history.

A multicenter study involving 1,380 neuroendocrine neoplasms reveals divergent c-MYC expression patterns between neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC). These findings could inform future research and therapeutic strategies targeting c-MYC in these diseases.

Not rare diseases news,news about your rare disease.

Earlier

Recent multi-omics profiling identifies homologous recombination repair hyperactivation as a therapeutic vulnerability in neuroendocrine cervical carcinoma. This discovery could inform future treatment strategies for this rare cancer type.

A case study published in PubMed details a patient with mixed neuroendocrine carcinoma and adenocarcinoma following ileal pouch-anal anastomosis. This research contributes to the understanding of rare cancer presentations in patients with surgical history.

A multicenter study involving 1,380 neuroendocrine neoplasms reveals divergent c-MYC expression patterns between neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC). These findings could inform future research and therapeutic strategies targeting c-MYC in these diseases.

Not rare diseases news,
news about your rare disease.